Last reviewed · How we verify
transdermal clonidine
Transdermal clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity, lowering blood pressure and heart rate.
Transdermal clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity, lowering blood pressure and heart rate. Used for Hypertension, Attention-deficit/hyperactivity disorder (ADHD).
At a glance
| Generic name | transdermal clonidine |
|---|---|
| Sponsor | Peking University People's Hospital |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clonidine binds to alpha-2 adrenergic receptors in the central nervous system, decreasing the release of norepinephrine and reducing sympathetic outflow. The transdermal formulation provides sustained drug delivery through the skin, maintaining therapeutic levels over extended periods. This mechanism results in vasodilation and reduced cardiac output, leading to antihypertensive effects.
Approved indications
- Hypertension
- Attention-deficit/hyperactivity disorder (ADHD)
Common side effects
- Dry mouth
- Drowsiness
- Dizziness
- Headache
- Constipation
- Skin irritation at patch site
- Rebound hypertension upon discontinuation
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) (PHASE3)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
- Use of Transdermal Clonidine in Trauma Patients (PHASE4)
- PeriOperative ISchemic Evaluation-2 Trial (PHASE3)
- Transdermal Clonidine in Chronic Hemodialysis Patients (NA)
- Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers (PHASE1)
- Anesthetics in Rhytidoplasty - A Comparison Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- transdermal clonidine CI brief — competitive landscape report
- transdermal clonidine updates RSS · CI watch RSS
- Peking University People's Hospital portfolio CI